Drug Therapy
News
Trial finds three drugs equally effective for established status epilepticus
Randomized study of fosphenytoin, valproate, and levetiracetam informs management of benzodiazepine-refractory disease.
Conference Coverage
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTE
New findings take aim at CAR T-cell therapy-related obstacles and highlight potential new paths forward.
Conference Coverage
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.
Conference Coverage
Combo elicits lasting responses in metastatic melanoma
NATIONAL HARBOR, MD. – In a phase 1/2 trial of previously untreated advanced melanoma patients, the combination of bempegaldesleukin and nivolumab...
News
Survey: Cancer-related pain, opioid use up since 2018
Almost half of patients with cancer did not use anything to manage related symptoms, according to an ASCO poll.
Conference Coverage
OA management guidelines forgo treatment hierarchy or order but emphasize severity, patient risk factors
ATLANTA – “For any individual patient, a single option may be chosen at a particular time point, perhaps with or without other options, and may be...
Conference Coverage
What’s new in hepatitis C: Four themes that dominated at the Liver Meeting
BOSTON – AASLD highlights included treatment of persons who inject drugs, new directions in pangenotypic therapy,...
Conference Coverage
Depression linked to persistent opioid use after hysterectomy
VANCOUVER – Women with preoperative depression were more likely to have a comorbid pain disorder, compared with...
Conference Coverage
Hepatitis B debrief: Key themes that emerged at AASLD
BOSTON – Hot topics included HBV natural history, novel therapies, and prevention.
News
FDA announces approval of fifth adalimumab biosimilar, Abrilada
Pfizer said that current plans are to launch the drug in the United States in 2023.